Modeling the public health impact of malaria vaccines for developers and policymakers

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Nunes, Julia K ^a,i   Cárdenas, Vicky ^a,b   Loucq, Christian ^a,j   Maire, Nicolas ^c,d   Smith, Thomas ^c,d   Shaffer, Craig ^e   Måseide, Kårstein ^f,g   Brooks, Alan ^c,d,h  

^a PATH Malaria Vaccine Initiative   (United States)

^b AERAS   (United States)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e not available   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g NORAD   (Norway)

^h PATH Malaria Vaccine Initiative   (France)

ⁱ not available   (India)

^j International Vaccine Institute   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ARTICLE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; FINANCIAL MANAGEMENT; FORECASTING; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH IMPACT ASSESSMENT; HUMAN; IMMUNIZATION; MALARIA; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MORTALITY; PLASMODIUM FALCIPARUM; PUBLIC HEALTH SERVICE; SENSITIVITY ANALYSIS;

AFRICA; HUMANS; MALARIA; MALARIA VACCINES; MODELS, STATISTICAL; PUBLIC HEALTH; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84879487659     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-295     Document Type: Article

References (50)

1. GAVI Alliance Guidelines for the preparation of proposals for GAVI/VF funding 2004, Geneva: GAVI, Second draft, Version 4, GAVI Alliance.
2. World Health Organization Vaccine introduction guidelines-adding a vaccine to a national immunization programme: decision and implementation 2005, Geneva: WHO, WHO/IVB/05.1, World Health Organization.
3. Mitchell S. Unsimple truths: science, complexity and policy 2009, Chicago: University of Chicago Press.
4. World Health Organization World malaria report 2012 2012, Geneva: WHO, World Health Organization.
5. Milstien J, Cohen JC, Olsen IT. An evaluation of GAVI alliance efforts to introduce new vaccines via the accelerated development and introduction plans (ADIPS) and the Hib initiative (HI) 2007, London: HLSP.
6. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(Suppl 1):S28-S38.
7. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008, 16:86-96. 10.1016/S0968-8080(08)32409-4, 19027626.
8. Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood) 2007, 26:1147-1158.
9. Victora CG. LiST: using epidemiology to guide child survival policymaking and programming. Int J Epidemiol 2010, 39:650-652. 10.1093/ije/dyq097, 20511605.
10. Jauregui B, Sinha A, Clark AD, Bolanos BM, Resch S, Toscano CM, et al. Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: lessons learned by PAHO's ProVac Initiative. Vaccine 2011, 29:1099-1106. 10.1016/j.vaccine.2010.11.075, 21144916.
11. Carneiro I, Smith L, Ross A, Roca-Feltrer A, Greenwood B, Schellenberg JA, et al. Intermittent preventive treatment for malaria in infants: a decision-support tool for sub-Saharan Africa. Bull World Health Organ 2010, 88:807-814. 10.2471/BLT.09.072397, 2971505, 21076561.
12. World Health Organization Report on the WHO quantitative immunization and vaccines related research (QUIVER): advisory committee meeting 2012, Geneva: WHO, World Health Organization.
13. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, et al. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. AmJTrop Med Hyg 2006, 75:1-10.
14. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010, 7(8):e1000324. 10.1371/journal.pmed.1000324, 2919425, 20711482.
15. Moorthy VS, Hutubessy R, Newman RD, Hombach J. Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses. Bull World Health Organ 2012, 90(11):864-6. 10.2471/BLT.12.107482, 3506408, 23226899.
16. Tediosi F, Hutton G, Maire N, Smith TA, Ross A, Tanner M. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. AmJTrop Med Hyg 2006, 75:131-143.
17. GAVI Alliance Independent expert committee recommendation for AMC pilot 2006, 4-27-2011. http://www.vaccineamc.org/files/iec_rec_pilot.pdf, GAVI Alliance.
18. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295.
19. Malaria Vaccine Funders Group Malaria vaccine technology roadmap 2006, 1-14-2011. http://www.malariavaccine.org/malvac-roadmap.php, Malaria Vaccine Funders Group.
20. UN Population Division World Population Prospects 2010, New York: UN, UN Population Division.
21. World Health Organization, United Nations Children's Fund Immunization summary: a statistical reference containing data through 2007 2009, New York: UNICEF, World Health Organization, United Nations Children's Fund.
22. World Health Organization Routine immunization coverage 2010, http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html, World Health Organization.
23. Oguntola S. Experts recommend inclusion of pneumococcal vaccine in immunisation programme Nigerian Tribune, 7-8-2010. http://www.tribune.com.ng/index.php/health-news/7924-experts-recommend-inclusion-of-pneumococcal-vaccine-in-immunisation-programme.
24. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg 2006, 75:19-31.
25. Ross A, Killeen GF, Smith T. Relationships of host infectivity to mosquitoes and asexual parasite density in Plasmodium falciparum. Am J Trop Med Hyg 2006, 75(Suppl 2):32-37.
26. Ross A, Maire N, Molineaux L, Smith T. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg 2006, 75:63-73.
27. Openmalaria A simulator of malaria epidemiology and control 2013, https://code.google.com/p/openmalaria/, Openmalaria.
28. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, Molineaux L, et al. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. 41. Am J Trop Med Hyg 2006, 75:11-18.
29. Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L. An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. AmJTrop Med Hyg 2006, 75:56-62.
30. INDEPTH Network Population, health and survival at INDEPTH sites 2002, Ottawa: IDRC, INDEPTH Network.
31. Smith T, Maire N, Ross A, Penny M, Chitnis N, Schapira A, et al. Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology 2008, 135:1507-1516. 10.1017/S0031182008000371, 18694530.
32. Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, et al. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-saharan Africa. Am J Trop Med Hyg 2006, 75:90-103.
33. Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One 2008, 3:e3193. 10.1371/journal.pone.0003193, 2527129, 18784833.
34. World Health Organization World Malaria Report 2008, Geneva: WHO, World Health Organization.
35. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, et al. A world malaria map: plasmodium falciparum endemicity in 2007. PLoS Med 2009, 6:e1000048. 2659708, 19323591.
36. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: plasmodium falciparum endemicity in 2010. Malar J 2011, 10:378. 10.1186/1475-2875-10-378, 3274487, 22185615.
37. Hay SI, Rogers DJ, Toomer JF, Snow RW. Annual plasmodium falciparum entomological inoculation rates (EIR) across Africa: literature survey, internet access and review. Trans R Soc Trop Med Hyg 2000, 94:113-127. 10.1016/S0035-9203(00)90246-3, 3204456, 10897348.
38. Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med Hyg 2006, 75:111-118.
39. Maire N, Aponte JJ, Ross A, Thompson R, Alonso P, Utzinger J, et al. Modeling a field trial of the RTS, S/AS02A malaria vaccine. Am J Trop Med Hyg 2006, 75:104-110.
40. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med 2012, 9:e1001157. 10.1371/journal.pmed.1001157, 3260300, 22272189.
41. Tediosi F, Maire N, Penny M, Studer A, Smith TA. Simulation of the cost-effectiveness of malaria vaccines. Malar J 2009, 8:127. 10.1186/1475-2875-8-127, 2701956, 19505328.
42. Griffiths UK, Korczak VS, Ayalew D, Yigzaw A. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 2009, 27:1426-1432. 10.1016/j.vaccine.2008.12.037, 19146901.
43. Robberstad B, Cairns J. Time preferences for health in northern Tanzania: an empirical analysis of alternative discounting models. PharmacoEconomics 2007, 25:73-88. 10.2165/00019053-200725010-00007, 17192119.
44. Hutton G, Tediosi F. The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. Am J Trop Med Hyg 2006, 75:119-130.
45. World Health Organization World malaria report 2006, World Health Organization.
46. Tediosi F, Maire N, Penny M, Studer A, Smith T. Simulation of the cost-effectiveness of malaria vaccines. Malar J 2009,
47. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
48. World Health Organization Most advanced malaria vaccine candidate and timing for policy recommendations 2012, Accessed 2-6-2012. http://www.who.int/vaccine_research/diseases/malaria/vaccine_candidate_policy/en/index.html, World Health Organization.
49. World Health Organization WHO-choice 2013, Available from: http://www.who.int/choice/costs/CER_thresholds/en/ [Accessed 26 June 2013], World Health Organization.
50. Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health 2011, 14:1028-1038. 10.1016/j.jval.2011.06.004, 22152171.